The influence of atorvastatin on walking performance in peripheral arterial disease

Vasa - Journal of Vascular Diseases

Volumn 38, Issue 2, 2009, Pages 155-159

  Bregar, U ^a   Poredoš, Pavel ^a   Sabovic M ^a   Jug, B ^a   Sebestjen M ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cholesterol lowering; Intermittent claudication; Peripheral arterial disease

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTERMITTENT CLAUDICATION; LIPID ANALYSIS; MALE; RANDOMIZED CONTROLLED TRIAL; WALKING; AGED; BLOOD; DOSE RESPONSE; DRUG EFFECT; EXERCISE TEST; LOW FAT DIET; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

AGED; ANTICHOLESTEREMIC AGENTS; ARTERIAL OCCLUSIVE DISEASES; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; DIET, FAT-RESTRICTED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PYRROLES; STATISTICS, NONPARAMETRIC; WALKING;

EID: 73149099631     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.38.2.155     Document Type: Article

References (17)

1. Aronow WS, Ahn C. Frequency of new coronary events in older person with peripheral arterial disease and serum low-density lipoprotein cholesterol or = 125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 90: 789-91.
2. Binaghi F, Fronteddu PF, Cannas F, Caredda E, Uras A, Garau P et al. Prevalence of peripheral arterial occlusive disease and associated risk factors in a sample of southern Sardinian population. Int Angiol 1994; 13: 233-45.
3. Blinc A, Poredos P. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. Eur J Clin Invest 2007; 37 (3): 157-164.
4. Brown BG, Zhao XQ, Sacco DE et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
5. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
6. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
7. Garg PK, Tian L, Criqui MH, Liu K, Ferrucci L, Guralnik JM et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006; 114: 242-8.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 306: 7-22.
9. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
10. Kinlay S, Plutzky J. Effect of lipid lowering therapy on vasomotion and endothelial function. Curr Cardiol Rep 1999; 1: 238-43.
11. Labs KH, Dormandy JA, Kurt AJ, Stuerzebecher CS, Hiatt WR. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease. Circulation 1999; 100: e75-e81.
12. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107: 757-61.
13. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108: 1481-6.
14. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patiebts with peripheral vascular disease. Am J Med 2003; 114: 359-64.
15. Regensteiner JG, Ware JE Jr, McCarthy WJ et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50: 1939-1946.
16. The TASC II Working Group. Inter-Society Consensus for the Management of PAD. Int Angiol 2007; 26 (2): 81-157.
17. Vasa M, Fichtscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary disease. Circulation 2001; 103: 2885-90.